← back to search

Mingzhu Zhou

Union Hospital ·
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research focused on Diffuse large B-cell lymphoma and Refractory (planetary science), with related work in Cohort, Lymphoma, Phases of clinical research. Notable publications include 'Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell...', 'Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from...', and 'Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma'.
h-index
citations
78
works
3
NIH funding
primary concept
email

Recent publications

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Blood 2023cited by 21position: middledoi
Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Blood 2022cited by 34position: middledoi
Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
Blood 2022cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Annie Yang · University of Rochester Medical Center1 papers (2022–2022)Sunil Babu · Fort Wayne Medical Institute1 papers (2022–2022)John Radford · University of Manchester1 papers (2022–2022)Georg Heß · Johannes Gutenberg University Mainz1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2022–2022)Dok Hyun Yoon · Sungkyunkwan University1 papers (2022–2022)David C. Turner · American Academy of Pediatrics1 papers (2022–2022) · 1 papers (2022–2022)Laurie H. Sehn · BC Cancer Agency1 papers (2022–2022)Diana Dunshee · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)Norma C. Gutiérrez · Consorci Institut D'Investigacions Biomediques August Pi I Sunyer1 papers (2022–2022)Keith Fay · St Vincent's Hospital Melbourne1 papers (2022–2022)Matthew J. Matasar · Rutgers, The State University of New Jersey1 papers (2022–2022)Martin Dreyling · Brazosport Eye Institute1 papers (2022–2022) · 1 papers (2022–2022)Adam J. Olszewski · Brown University1 papers (2022–2022) · 1 papers (2022–2022)Sung‐Soo Yoon · Seoul National University1 papers (2022–2022)